Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Gabriela S. Hobbs; Amritha Varshini Hanasoge Somasundara; Maria Kleppe; Rivka Litvin; Maria Arcila; Jihae Ahn; Anna Sophia McKenney; Kristina Knapp; Ryan Ptashkin; Howard Weinstein; Murk Hein Heinemann; Jasmine Francis; Suzanne Chanel; Ellin Berman; Michael Mauro; Martin S. Tallman; Mark L. Heaney; Ross L. Levine; Raajit K. Rampal

doi:10.3324/haematol.2017.177600

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Gabriela S. Hobbs, Amritha Varshini Hanasoge Somasundara, Maria Kleppe, Rivka Litvin, Maria Arcila, Jihae Ahn, Anna Sophia McKenney, Kristina Knapp, Ryan Ptashkin, Howard Weinstein, Murk Hein Heinemann, Jasmine Francis, Suzanne Chanel, Ellin Berman, Michael Mauro, Martin S. Tallman, Mark L. Heaney, Ross L. Levine, Raajit K. Rampal^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English (US)
Pages (from-to)	e5-e9
Journal	Haematologica
Volume	103
Issue number	1
DOIs	https://doi.org/10.3324/haematol.2017.177600
State	Published - Jan 2018

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2017.177600

Cite this

Hobbs, G. S., Hanasoge Somasundara, A. V., Kleppe, M., Litvin, R., Arcila, M., Ahn, J., McKenney, A. S., Knapp, K., Ptashkin, R., Weinstein, H., Heinemann, M. H., Francis, J., Chanel, S., Berman, E., Mauro, M., Tallman, M. S., Heaney, M. L., Levine, R. L., & Rampal, R. K. (2018). Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica, 103(1), e5-e9. https://doi.org/10.3324/haematol.2017.177600

@article{5d52fba5bf9947b19d7facf62cb694d3,

title = "Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms",

author = "Hobbs, {Gabriela S.} and {Hanasoge Somasundara}, {Amritha Varshini} and Maria Kleppe and Rivka Litvin and Maria Arcila and Jihae Ahn and McKenney, {Anna Sophia} and Kristina Knapp and Ryan Ptashkin and Howard Weinstein and Heinemann, {Murk Hein} and Jasmine Francis and Suzanne Chanel and Ellin Berman and Michael Mauro and Tallman, {Martin S.} and Heaney, {Mark L.} and Levine, {Ross L.} and Rampal, {Raajit K.}",

note = "Funding Information: 1Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School;2Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; 3Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center;4Department of Pathology, Memorial Sloan Kettering Cancer Center;5Driskill Graduate Program in Life Sciences, Feinberg School of Medicine, Northwestern University;6Gerstner Sloan Kettering Graduate School of Biomedical Sciences, and Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program;7Center for Epigenetics Research Memorial Sloan Kettering Center;8Cardiology Service, Department of Medicine Memorial Sloan Kettering Cancer Center;9Department of Surgery, Memorial Sloan Kettering Cancer Center and 10Department of Medicine, Columbia University Medical Center, USA Funding: this work was supported by funding from Novartis Pharmaceuticals; Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748); NCI 1K08CA188529-01 (RKR); KK12CA087723-14 (GSH); NCI R01CA173636 (RLL); K99 HL122503-01A1 (MK); NIH National Institute of General Medical Sciences Grant T32 GM007739 and NCI F30CA18349 (ASM). Correspondence: rampalr@mskcc.org doi:10.3324/haematol.2017.177600 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org. Funding Information: Funding: this work was supported by funding from Novartis Pharmaceuticals; Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center(P30 CA008748); NCI 1K08CA188529-01 (RKR); KK12CA087723-14 (GSH); NCI R01CA173636 (RLL); K99 HL122503-01A1 (MK); NIH National Institute of General Medical Sciences Grant T32 GM007739 and NCI F30CA18349 (ASM).",

year = "2018",

month = jan,

doi = "10.3324/haematol.2017.177600",

language = "English (US)",

volume = "103",

pages = "e5--e9",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

Hobbs, GS, Hanasoge Somasundara, AV, Kleppe, M, Litvin, R, Arcila, M, Ahn, J, McKenney, AS, Knapp, K, Ptashkin, R, Weinstein, H, Heinemann, MH, Francis, J, Chanel, S, Berman, E, Mauro, M, Tallman, MS, Heaney, ML, Levine, RL & Rampal, RK 2018, 'Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms', Haematologica, vol. 103, no. 1, pp. e5-e9. https://doi.org/10.3324/haematol.2017.177600

TY - JOUR

T1 - Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

AU - Hobbs, Gabriela S.

AU - Hanasoge Somasundara, Amritha Varshini

AU - Kleppe, Maria

AU - Litvin, Rivka

AU - Arcila, Maria

AU - Ahn, Jihae

AU - McKenney, Anna Sophia

AU - Knapp, Kristina

AU - Ptashkin, Ryan

AU - Weinstein, Howard

AU - Heinemann, Murk Hein

AU - Francis, Jasmine

AU - Chanel, Suzanne

AU - Berman, Ellin

AU - Mauro, Michael

AU - Tallman, Martin S.

AU - Heaney, Mark L.

AU - Levine, Ross L.

AU - Rampal, Raajit K.

N1 - Funding Information: 1Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School;2Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; 3Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center;4Department of Pathology, Memorial Sloan Kettering Cancer Center;5Driskill Graduate Program in Life Sciences, Feinberg School of Medicine, Northwestern University;6Gerstner Sloan Kettering Graduate School of Biomedical Sciences, and Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program;7Center for Epigenetics Research Memorial Sloan Kettering Center;8Cardiology Service, Department of Medicine Memorial Sloan Kettering Cancer Center;9Department of Surgery, Memorial Sloan Kettering Cancer Center and 10Department of Medicine, Columbia University Medical Center, USA Funding: this work was supported by funding from Novartis Pharmaceuticals; Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748); NCI 1K08CA188529-01 (RKR); KK12CA087723-14 (GSH); NCI R01CA173636 (RLL); K99 HL122503-01A1 (MK); NIH National Institute of General Medical Sciences Grant T32 GM007739 and NCI F30CA18349 (ASM). Correspondence: rampalr@mskcc.org doi:10.3324/haematol.2017.177600 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org. Funding Information: Funding: this work was supported by funding from Novartis Pharmaceuticals; Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center(P30 CA008748); NCI 1K08CA188529-01 (RKR); KK12CA087723-14 (GSH); NCI R01CA173636 (RLL); K99 HL122503-01A1 (MK); NIH National Institute of General Medical Sciences Grant T32 GM007739 and NCI F30CA18349 (ASM).

PY - 2018/1

Y1 - 2018/1

UR - http://www.scopus.com/inward/record.url?scp=85040079612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040079612&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.177600

DO - 10.3324/haematol.2017.177600

M3 - Letter

C2 - 29051283

AN - SCOPUS:85040079612

VL - 103

SP - e5-e9

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this